Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952313 · ClinicalTrials.gov registry record · NA
Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study
A NA study, sponsored by Spirox.
- Completed
- Registry status
- NA
- Development phase
- 113
- Enrollment target
NCT02952313: Completed NA study, sponsored by Spirox.
NCT02952313 is a NA study that has completed, run by Spirox. The registered enrollment target is 113 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02952313, a NA study, has completed, sponsored by Spirox.
- COMPLETED
- Registry status
- NA
- Development phase
- 113 participants
- Enrollment target
Study Summary
This study is being conducted to obtain outcomes data in subjects with severe to extreme class NOSE scores undergoing placement of the Spirox Latera Implant with or without concurrent septoplasty and/or turbinate reduction procedures in an operating room setting.
Primary Outcome
Responder is defined as a participant who has improvement of at least 1 Nasal Obstruction Symptom Evaluation (NOSE) class or at least 20% NOSE score reduction. NOSE scores. NOSE scores can range from 5 to 100, with higher scores indicating worse symptoms. Classes are mild (5-25), moderate (30-50), severe (55-75), and severe (80-100).
Interventions
- DEVICE Nasal Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2016-09 |
| Est. Completion | 2019-08 |
| Phase | NA |
What the finished NCT02952313 record still lists
NCT02952313 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Nasal Implant is the first listed.
NCT02952313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02952313 about?
NCT02952313 is a clinical study titled "Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study". This study is being conducted to obtain outcomes data in subjects with severe to extreme class NOSE scores undergoing placement of the Spirox Latera Implant with or without concurrent septoplasty and/or turbinate reduction procedures in an operating room setting.
What is the current status of trial NCT02952313?
This trial is currently completed. It is a NA study. The enrollment target is 113 participants. The study started on 2016-09. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02952313?
The interventions under investigation include: Nasal Implant (DEVICE).
Who is sponsoring clinical trial NCT02952313?
This trial is sponsored by Spirox, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02952313's enrollment target sits among peer trials
113 813th of 2000 higher than 1,188 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia